Pharmaceutical Benefits Regulations (Amendment)

Overview

The Pharmaceutical Benefits Regulations 1950, made under the Pharmaceutical Benefits Act 1947-1949, were enacted to provide a regulatory framework governing the supply and administration of pharmaceutical benefits in Australia. The regulations were introduced to address the need for more comprehensive controls over the prescription and supply of pharmaceuticals, particularly in relation to ensuring the safe and effective use of certain medications. The enactment of these regulations was authorised by the Governor-General in and over the Commonwealth of Australia, acting on the advice of the Federal Executive Council. The policy objective, as outlined in the regulations, is to refine the administration of pharmaceutical benefits, thereby enhancing public health and safety by regulating the prescription practices of medical practitioners and the supply of certain medications.

Scope and Application

The Pharmaceutical Benefits Regulations, made under the Pharmaceutical Benefits Act 1947-1949, apply to medical practitioners, pharmaceutical chemists, and approved hospital authorities involved in the supply and payment of pharmaceutical benefits. These regulations govern the writing and dispensing of prescriptions, the supply of pharmaceutical benefits, and the payment to approved hospital authorities. They have a national reach as they pertain to the Commonwealth of Australia, operating across all states and territories. The regulations include specific restrictions on the prescribing of certain drugs, such as streptomycin and dihydrostreptomycin, and limit the number of prescriptions a medical practitioner can write on a single day for the same pharmaceutical benefit to the same person. Furthermore, they address the writing of prescriptions for dangerous drugs, ensuring that a medical practitioner cannot write multiple prescriptions on the same form for these substances. The regulations can be extended or restricted through subordinate instruments, allowing for adjustments in the implementation and enforcement of these provisions.

Key Provisions

The main provisions of the Statutory Rules 1950 No. 62, which are regulations under the Pharmaceutical Benefits Act 1947-1949, introduce several amendments to the Pharmaceutical Benefits Regulations. Regulation 12 is amended to include provisions that ensure prescriptions are written for one person only and do not prescribe the same benefit twice (sub-regulation (2)(da), (db)). Additionally, it prohibits medical practitioners from writing multiple prescriptions for the same pharmaceutical benefit for the same person on the same day (regulation 12a). In cases where a pharmaceutical benefit is classified as a dangerous drug, a medical practitioner is not allowed to write another prescription on the same form (regulation 12b). The regulations also extend the list of drugs for which prescribing is restricted to include Streptomycin and Dihydrostreptomycin (regulation 14(3)). Furthermore, regulation 31 allows for the earlier application of determinations concerning payments to approved hospital authorities, provided they do not reduce payments made prior to the publication date of the determination (regulation 31(4a)). The obligations imposed by these regulations require medical practitioners to adhere to specific guidelines when writing prescriptions for pharmaceutical benefits. This includes ensuring that each prescription is for a single person, does not prescribe the same benefit twice, and does not include multiple prescriptions for the same pharmaceutical benefit on the same day. For dangerous drugs, a practitioner must ensure they only write one prescription per form. These regulations are designed to maintain the integrity of the pharmaceutical benefits system and ensure that prescriptions are issued responsibly and in accordance with legal requirements. Failure to comply with these regulations can result in various consequences. For example, writing a prescription in contravention of regulation 12b disqualifies the recipient from receiving the pharmaceutical benefit (regulation 12b(2)). The regulations do not specify particular penalties for breaches but suggest that breaches could lead to the disqualification of the benefit. In a broader context, non-compliance with regulations under the Pharmaceutical Benefits Act could potentially lead to civil or criminal penalties, depending on the nature and severity of the breach. The amendments to the Third Schedule redefine the "basic amount" for pharmaceutical benefits, altering the method for determining prevailing prices and affecting the calculations for certain benefits. These changes are intended to update the pricing structure and ensure consistency in the application of the Pharmaceutical Benefits Regulations. The amendments made by regulation 5(2) do not apply to payments for pharmaceutical benefits supplied before the first day of October, 1950, ensuring a smooth transition to the new definitions.